Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced today that it will acquire 23andMe for a purchase price of $256 ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...

Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or ...

Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

Regeneron Pharmaceuticals ... It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

Lilly’s drug becomes an oral alternative to Sanofi and Regeneron’s biologic therapy ... a second-line option for moderate to severe atopic dermatitis in 2018. Both drugs should be used only ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... that the drug shares with Sanofi and Regeneron’s blockbuster AD therapy Dupixent ...